Periodontal ageing and its management via pharmacological glucose modulation
- PMID: 39917674
- PMCID: PMC11797871
- DOI: 10.3389/fdmed.2024.1415960
Periodontal ageing and its management via pharmacological glucose modulation
Abstract
Periodontal disease (PD), a widespread non-communicable disease, affects over 90% of the global population with no known cure. Current management strategies focus on the stabilisation of disease progression, which is successfully achieved to a limited extent. Yet the never-ending battle between bacteria and the gingiva involves a complex interplay between genetic, microbial and environmental factors, demanding innovative approaches to improve the prevention and stabilisation of this disease. Glucose is the body's source of energy and research has shown that dysregulation of the glucose metabolism impacts PD establishment and progression, as well as the development of systemic non-communicable diseases. Metformin, a drug known for its efficacy in diabetes treatment via controlling glucose metabolism, also demonstrated cardioprotective effects, increased longevity, and anti-inflammatory properties. Metformin has been used in gel format in clinical trials for non-surgical treatment of PD, however, its systemic use in normoglycemic individuals with PD is less explored. A recent study presented compelling evidence of metformin's preventive potential, impacting PD and markers of systemic health involved in metabolic health linked to improvement of lifespan. Therefore, this review discusses the aspects of ageing as a concept in the periodontium and the potential benefits of modulating glucose metabolism through metformin to prevent PD, indirectly preventing systemic conditions involved in multi-morbidity, addressing a critical gap in current management. It also examines the choice between implementation of behaviour change and/or medication as a strategy to add to current oral hygiene strategies. Finally, it discusses the ethical implications of prescribing systemic medication in dentistry.
Keywords: ageing; glycaemic control; metformin; multimorbidity prevention; periodontal disease; preventive medicine.
© 2024 Neves, Savchenko, Daly and Sharpe.
Conflict of interest statement
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Figures
References
-
- Savulescu J. Genetic interventions and the ethics of enhancement of human beings. In: Steinbock B, editor. The Oxford Handbooks of Bioethics. Oxford: Oxford University Press; (2009). p. 516–35.
-
- Ramseier CA, Woelber JP, Kitzmann J, Detzen L, Carra MC, Bouchard P. Impact of risk factor control interventions for smoking cessation and promotion of healthy lifestyles in patients with periodontitis: a systematic review. J Clin Periodontol. (2020) 47(Suppl 22):90–106. 10.1111/jcpe.13240 - DOI - PubMed
Publication types
LinkOut - more resources
Full Text Sources
Miscellaneous
